Jun 26, 2026
17 MIN READ

When Will I Notice Weight Loss on Wegovy?

Most patients notice their first weight loss signs within 2–4 weeks of starting semaglutide, though individual results vary based on metabolism, dosage, and lifestyle factors. PlexusDx compounded semaglutide begins at $149/month with no dose-based pricing increases.

GLP-1 weight loss starts at $129/mo Provider-reviewed options. No membership fees.

See if you qualify →

Jun 26, 2026
17 MIN READ

when will i notice weight loss on wegovy? — PlexusDx GLP-1 education

Last reviewed: June 26, 2026

Last updated: June 26, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide, a GLP-1 receptor agonist originally developed for diabetes management, has become a popular weight loss medication because it reduces appetite and helps regulate blood sugar. Most people wonder how soon they'll see results—and the answer depends on your starting dose, your body's response, and your overall health picture. Understanding realistic weight loss timelines helps you stay motivated and track whether your treatment is working effectively.

Typical Weight Loss Timeline: First 4 Weeks

During your first month on semaglutide, appetite suppression typically kicks in within the first 7–10 days as the medication reaches therapeutic levels in your bloodstream. Many patients report eating smaller portions naturally and feeling full faster, even before significant weight loss appears on the scale. This early appetite reduction is a sign that the medication is working, though the number on the scale may drop slowly at first—often 1–3 pounds in week one, depending on your starting dose and water retention.

By the end of week four, most patients beginning semaglutide therapy see measurable weight loss of 3–6 pounds, assuming consistent adherence and no major dietary changes in the opposite direction. The rate depends heavily on your baseline weight, metabolism, and how aggressively your prescriber increases your dose. Starting with a low dose (typically 0.25 mg for injections or lower for oral formulations) means slower initial results but easier tolerability and fewer gastrointestinal side effects.

Months 2–3: Acceleration and Dose Escalation

As your body adapts to semaglutide and your prescriber titrates your dose upward, weight loss acceleration usually begins around week 5–8. Most dose-escalation protocols increase your injection dose every 4 weeks, meaning by week 8 you may be at 0.5 mg (or higher), triggering stronger appetite suppression and more noticeable fat loss. Patients commonly report losing 5–10 pounds during the second month, with cumulative losses reaching 10–15 pounds by month three, though individual variation is substantial.

Your genetics play a significant role in how your body responds to semaglutide during this window. The PlexusDx Precision Peptide Genetic Test identifies variants in your GLP1R gene (rs6923761) and GIPR gene (rs1800437) that predict whether your appetite-suppression response will be robust or modest. Knowing your genetic predisposition allows your PlexusDx provider to optimize your dose strategy and potentially recommend combination therapies like GLP-Squared if single-agent semaglutide isn't producing expected results.

Months 4–6: Steady State and Plateau Recognition

By month four, most patients reach their maintenance dose (typically 0.5–1.0 mg weekly for injections), and weight loss often enters a steady-state phase of 1–2 pounds per week. Total weight loss at six months commonly ranges from 15–25 pounds for most people, though some achieve 30+ pounds depending on adherence, diet quality, and exercise consistency. It's important to recognize that weight loss plateaus are normal and don't indicate treatment failure—your body is adjusting to your new weight and medication regimen.

If your weight loss slows or stops between months four and six, your prescriber may recommend maintaining your current dose while optimizing your nutrition and movement patterns, or exploring whether a higher dose is appropriate. Patients who hit a plateau sometimes benefit from PlexusDx's genetic insights into their FTO gene variant (rs9939609) and MC4R variant (rs17782313), which influence fat storage and satiety signaling. Understanding whether your plateau is genetic, behavioral, or metabolic helps guide next-step decisions without unnecessary medication adjustments.

Factors That Speed Up or Slow Down Your Results

Your weight loss speed depends on multiple variables beyond just the medication: starting weight (people with higher baseline weight often lose faster initially), age, baseline metabolism, sleep quality, stress levels, and diet composition all play major roles. Patients who combine semaglutide with consistent strength training and adequate protein intake often see faster fat loss and better body composition than those relying on medication alone. Alcohol consumption, frequent high-calorie foods, and poor sleep can blunt semaglutide's effects, slowing results by 30–50 percent or more.

Starting dose matters significantly—patients who begin at 0.25 mg injections see gentler early results but fewer side effects, while those tolerating rapid escalation may notice faster week-by-week changes. PlexusDx compounded semaglutide injections start at $149/month flat, with your dose potentially increasing over time, but your price remaining the same—removing cost barriers to dose optimization. Conversely, some patients respond excellently to lower doses and plateau naturally, while others require maintenance doses of 1.0 mg or higher to achieve meaningful results.

When to Expect Plateau and Long-Term Maintenance

Most patients experience their steepest weight loss during months 1–4, then enter a maintenance phase where weekly losses drop to 0.5–1.5 pounds by month six and beyond. This plateau is not a failure of semaglutide—it reflects your body reaching a new metabolic equilibrium at a lower weight. Continuing semaglutide during maintenance is critical because stopping the medication typically results in rapid weight regain as appetite hormones rebound within weeks to months.

Long-term data shows that patients who remain on semaglutide maintain their weight loss better than those who discontinue, suggesting ongoing GLP-1 receptor activation is necessary for sustained results. If your plateau occurs earlier than expected (before month three) or your weight loss is significantly slower than outlined here, discussing genetic testing or alternative formulations—such as PlexusDx oral semaglutide or GLP-Squared combination therapy—with your provider is warranted. The goal is finding your optimal dose and formulation to maximize results while minimizing side effects.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Can I see weight loss in the first week of semaglutide?

Yes—many patients experience 1–3 pounds of weight loss in week one, primarily from reduced appetite and water weight. However, this initial loss often slows after week two as your body adjusts; the meaningful, sustainable fat loss typically accelerates during weeks 3–4 and beyond.

What does research say about semaglutide weight loss timelines?

Clinical trials show semaglutide produces average weight loss of 10–15 percent of baseline body weight over 68 weeks, with most loss occurring in months 1–5. Patients on higher maintenance doses (1.0 mg weekly) achieved approximately 15 percent average loss, while those on lower doses saw 7–10 percent average loss.

Is PlexusDx compounded semaglutide as effective as brand-name Wegovy?

PlexusDx compounded semaglutide is formulated by licensed 503A compounding pharmacies to match the active pharmaceutical ingredient in brand-name products; efficacy depends on dose and adherence, not brand name. Starting at $149/month, PlexusDx removes cost barriers that prevent many patients from accessing consistent semaglutide therapy.

What if I'm not losing weight after 4 weeks on semaglutide?

Minimal weight loss at four weeks may indicate a dose that's too low for your metabolism, medication adherence issues, or significant dietary offset. Discuss dose escalation with your provider; if concerned about genetic factors, the PlexusDx Precision Peptide Genetic Test identifies GLP1R and GIPR variants that predict your response and may guide combination therapy decisions.

Does PlexusDx genetic testing predict my semaglutide weight loss timeline?

The PlexusDx Precision Peptide Genetic Test analyzes 14 metabolic pathways and 49 peptides, including GLP1R rs6923761 and GIPR rs1800437 variants that influence appetite suppression strength and timeline. Patients with favorable genetic profiles typically see faster, more robust results; those with less favorable variants may need higher doses or combination therapy like GLP-Squared to achieve similar outcomes.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves